Table 2 Effect of BRCA1 and BRCA2 mutations on kidney cancer risk
From: Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
Mutation subjects | Number of carriers/total (frequency %) | OR | 95% CI | p-value |
|---|---|---|---|---|
BRCA1 | ||||
5328 insC | ||||
Controls | 14/4000 (0.003) | 1.0 | ||
Cases | 3/688 (0.004) | 1.2 | 0.35–4.35 | 1.0 |
C61G | ||||
Controls | 2/4000 (0.0005) | 1.0 | ||
Cases | 0/688 | – | – | – |
4153 delA | ||||
Controls | 1/4000 (0.0002) | 1.0 | ||
Cases | 0/688 | – | – | – |
All BRCA1 | ||||
Controls | 17/4000 (0.004) | 1.0 | ||
Cases | 3/688 (0.004) | 1.0 | 0.29–3.51 | 1.0 |
BRCA2 | ||||
C5972T | ||||
Controls | 159/2791(0.06) | 1.0 | ||
Cases | 50/688 (0.07) | 1.3 | 0.93–1.80 | 0.1 |